Kosan Biosciences Inc. and Roche Holding AG ended their five-year collaboration to develop and commercialize epothilones, anticancer agents that inhibit cell division. (BioWorld Today)

The phrase "rheumatoid arthritis" almost right away calls to mind Genentech Inc.'s Rituxan (rituximab, which targets the CD20 antigen, for RA and non-Hodgkin's lymphoma). (BioWorld Financial Watch)

Shares of Israel-based Protalix BioTherapeutics Inc. crashed on word that the company priced 10 million shares of its stock at only $5 per share, as Wall Street cut the firm's market cap - hefty after last summer's merger with the shell firm Orthodontix Inc. - severely down to size. (BioWorld Today)